Morgan Stanley Cyclerion Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.43 - $0.9 $3,762 - $7,875	8,751 Added 266.07%	12,040 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $18.8 $45 - $2,049	-109 Reduced 3.21%	3,289 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $1,074 - $33,724	-1,853 Reduced 35.29%	3,398 $3,000
Q2 2022 Oct 27, 2022	SELL	$0.47 - $1.29 $15,948 - $43,774	-33,934 Reduced 86.6%	5,251 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.47 - $1.29 $15,948 - $43,774	-33,934 Reduced 86.6%	5,251 $3,000
Q1 2022 Oct 27, 2022	BUY	$0.96 - $1.78 $32,576 - $60,402	33,934 Added 646.24%	39,185 $43,000
Q1 2022 May 13, 2022	SELL	$0.96 - $1.78 $32,332 - $59,950	-33,680 Reduced 46.22%	39,185 $43,000
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $2,563 - $4,912	-1,643 Reduced 2.21%	72,865 $125,000
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $203,406 - $307,718	74,508 New	74,508 $229,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $145M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.